Quick Answer
Arbutus Biopharma Corp reported Diluted EPS of $0.17 per share (loss) for fiscal year 2025.
Arbutus Biopharma Corp Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$0.17 | +55.3% |
| 2024 | -$0.38 | +13.6% |
| 2023 | -$0.44 | +4.3% |
| 2022 | -$0.46 | +44.6% |
| 2021 | -$0.83 | +17.0% |
| 2020 | -$1.00 | +17.4% |
| 2018 | -$1.21 | +22.4% |
| 2017 | -$1.56 | +78.5% |
| 2016 | -$7.24 | -424.6% |
| 2015 | -$1.38 | +23.3% |
| 2014 | -$1.80 | -95.7% |
| 2013 | -$0.92 | -144.4% |
| 2012 | $2.07 | +332.6% |
| 2011 | -$0.89 | +25.8% |
| 2010 | -$1.20 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.04 | +60.0% | -500.0% |
| June 30, 2025 | $0.01 | +109.1% | +107.7% |
| March 31, 2025 | -$0.13 | -30.0% | -30.0% |
| September 30, 2024 | -$0.10 | +16.7% | +9.1% |
| June 30, 2024 | -$0.11 | -10.0% | -10.0% |
| March 31, 2024 | -$0.10 | +0.0% | +16.7% |
| September 30, 2023 | -$0.12 | +0.0% | -20.0% |
| June 30, 2023 | -$0.10 | +0.0% | +0.0% |
- Arbutus Biopharma Corp showed an increase of +55.3% in Diluted EPS compared to the prior fiscal year.
- Over the 2010–2025 period, Arbutus Biopharma Corp’s diluted eps has grown by 85.8% (from $1.20 per share (loss) to $0.17 per share (loss)).
- The most recent figure is from Arbutus Biopharma Corp’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 23, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: